A case report has described the use of amivantamab in this scenario. Briefly, the patient was diagnosed at age 67 with stage IV EGFR L858R NSCLC and was found to have EGFR T790M mutation upon progression on erlotinib as well as a G796S mutation upon progression on osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.